|

mirvetuximab soravtansine (MIRV; IMGN853) Clinical Trials

1 actively recruiting trial across 1 location

Pipeline

Phase 2: 1

Top Sponsors

  • University of Alabama at Birmingham1

Indications

  • Fallopian Tube1
  • Primary Peritoneal Cancer1
  • Ovarian Cancer1
  • Cancer1

Birmingham, Alabama1 trial

Study of Carboplatin and Mirvetuximab Soravtansine in First-Line Treatment of Patients Receiving Neoadjuvant Chemotherapy With Advanced-Stage Ovarian, Fallopian Tube or Primary Peritoneal Cancer

University of Alabama at Birmingham Womens & Infants Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.